In a retrospective clinical study, anti-DPP4 inhibitors were found to decrease the risk of HCC in patients with chronic hepatitis C infection and type 2 diabetes mellitus (T2DM) [167]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.